ImmunoGenesis
Phase 1/2We are rapidly translating the most cutting-edge discoveries from academic tumor immunology into drugs optimized for treating the majority of patients who have "cold" cancers refractory to currently available immunotherapy.
Founded
2016
Focus
Small Molecules
About
We are rapidly translating the most cutting-edge discoveries from academic tumor immunology into drugs optimized for treating the majority of patients who have "cold" cancers refractory to currently available immunotherapy.
Funding History
2Total raised: $15.5M
Series A$12MCancer Focus FundJan 15, 2022
Seed$3.5MUndisclosedMay 15, 2020
Company Info
TypePrivate
Founded2016
LocationHouston, United States
StagePhase 1/2
Contact
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile